🇯🇵·5d agoIndustry
Shionogi Announces Approval in Japan of a Supplemental Indication for XOCOVA® (Ensitrelvir Fumaric Acid) for the Post-Exposure Prophylaxis of COVID-19.
Publisher
S
Shionogi (IR News)
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on shionogi.com
Leave the platform to read the original full article on the publisher site.
Source: Shionogi (IR News)
Scope: Industry
Related coverage
More related coverage
Shionogi (IR News)·1d ago
Notice Regarding Bridge Loan Financing in Connection with an Additional Investment in ViiV Healthcare Ltd
Lundbeckfonden (News)·2d ago
The Lundbeck Foundation Annual Report 2025
In 2025, the Lundbeck Foundation delivered strong financial results and maintained a high level of g...
InflaRx·9h ago
Guggenheim SMID Cap Biotech Conference
InflaRx·9h ago